Manish A. Shah, MD

Frontline HER2-positive gastric cancer trials test T-DXd combos and TIGIT/PD-L1 bispecifics, aiming to improve survival beyond trastuzumab.

Experts weigh T‑DXd as second-line HER2+ gastric cancer therapy, stressing rebiopsy/ctDNA and vigilant pneumonitis risk.

Experts weigh T‑DXd for HER2+ gastric cancer after prior therapy, stressing rebiopsy or ctDNA confirmation and vigilant pneumonitis monitoring.

Clinicians share real-world tips to prevent and manage zanidatamab-related diarrhea, using early loperamide, patient counseling, follow-up calls, and supportive care.

Experts weigh using triplet immunotherapy plus chemo for PD‑L1–negative patients, balancing survival gains, side effects, and FDA approval in first-line care.

New trial updates tease stronger survival with zanidatumab combos; two analyses ahead may clarify OS, biomarkers, and tislelizumab’s added value.

New HER2+ gastric cancer data show triplet immunotherapy boosts survival and durable responses, hinting immune activation beyond HER2 targets.

HORIZON GEA 01 shows zanidatamab regimens significantly improve survival in HER2-positive gastric, esophageal, and GEJ cancer, while PD-L1 testing differences raise key questions for treatment choice.

Experts debate PD‑L1 testing in HER2+ metastatic gastric cancer as new trial data reshapes when to add immunotherapy.

Zanidatamab’s dual HER2 binding shows striking single-agent activity in gastric and biliary cancers, hinting at synergy beyond pertuzumab-trastuzumab blockade.

Experts unpack zanidatamab’s dual HER2 binding, why JACOB nearly succeeds, and what standout gastric and biliary cancer responses mean next.

Clinicians explain zanidatamab’s action and HORIZON-GEA-01

Manish A. Shah, MD, discusses the PFS benefit with zanidatamab plus chemotherapy with/without tislelizumab in HER2-positive GEA regardless of PD-L1 status.

Manish A. Shah, MD, discusses 5-year outcomes from the KEYNOTE-590 trial of frontline pembrolizumab plus chemotherapy in patients with esophageal cancer.

Manish A. Shah, MD, discusses the potential clinical implications of the ongoing phase 3 GLOW trial in Claudin 18.2-positive, HER2-negative gastric/gastroesophageal junction adenocarcinoma.

Manish A. Shah, MD, discusses the exciting updated results of the phase 2 DESTINY-Gastric01 study with fam-trastuzumab deruxtecan-nxki in HER2-expressing advanced gastric or gastroesophageal junction adenocarcinoma.

Manish A. Shah, MD, discusses biomarkers of response to immunotherapy gastric/gastroesophageal cancer.

Manish A. Shah, MD, discusses an optimal sequencing strategy in gastroesophageal cancer.

Manish A. Shah, MD, discusses the role of immunotherapy in gastroesophageal cancer.

Manish A. Shah, MD, discusses ongoing efforts to improve immunotherapy in gastric and gastroesophageal junction cancer.

Manish A. Shah, MD, discusses biomarkers in gastric and gastroesophageal junction cancer.

Manish A. Shah, MD, discusses the use of trastuzumab biosimilars in gastric cancer.

Manish A. Shah, MD, director of gastrointestinal oncology and chief of Solid Tumor Service at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the BRIGHTER study in patients with gastric and gastroesophageal junction (GEJ) adenocarcinoma.

Manish A. Shah, MD, director of gastrointestinal oncology and chief of Solid Tumor Service at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses challenges with immunotherapy in esophageal cancer.

Manish A. Shah, MD, director of gastrointestinal oncology and chief of Solid Tumor Service at Weill Cornell Medicine/NewYork-Presbyterian Hospital, highlights immunotherapy for esophageal cancer.

Manish A. Shah, MD, director of gastrointestinal oncology and chief of Solid Tumor Service at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the relationship between helicobacter pylori (H. pylori) and immune response in gastric cancer.

Manish A. Shah, MD, director of gastrointestinal oncology, Weill Cornell Medicine/New York-Presbyterian Hospital, discusses risk factors for patients with early-onset colorectal cancer (CRC).

Manish A. Shah, MD, director of gastrointestinal oncology, Weill Cornell Medicine/New York-Presbyterian Hospital, discusses the difference in treatment of left- and right-sided tumors in colorectal cancer.

Manish A. Shah, MD, director of gastrointestinal oncology, Weill Cornell Medicine/New York-Presbyterian Hospital, discusses the increase in prevalence of early-onset colorectal cancer (CRC).

Manish A. Shah, MD, director of gastrointestinal oncology, Weill Cornell Medicine/New York-Presbyterian Hospital, discusses indications of early-onset colorectal cancer (CRC).